domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md

@@ -74,3 +74,10 @@ Noom's microdose GLP-1Rx users showed 77.8% engagement with the app for 4+ weeks
 **Source:** Omada Health clinical outcomes data, March 2026
 
 Omada members who persisted on GLP-1 for 12 months achieved 18.4% average weight loss and 44% greater weight loss on semaglutide versus real-world evidence, suggesting behavioral support improves not just persistence but also on-medication efficacy.
+
+
+## Supporting Evidence
+
+**Source:** Omada Health FY2025 earnings report, March 5, 2026
+
+Omada's Enhanced GLP-1 Care Track achieved 67% persistence at 12 months versus 47-49% comparison cohort, representing 18-20 percentage point improvement. Persistent members achieved 18.4% average weight loss at 12 months; overall cohort 16.3% (44% better than semaglutide real-world evidence). This confirms behavioral support creates measurable persistence and outcome improvements.

inbox/archive/health/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md

@@ -7,10 +7,13 @@ date: 2026-03-05
 domain: health
 secondary_domains: []
 format: earnings-report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-08
 priority: high
 tags: [Omada, digital-health, GLP-1, behavioral-health, atoms-to-bits, VBC, employer-market, IPO]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content